Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an announcement.
Ondine Biomedical Inc., a leader in light-activated antimicrobial treatments, announced the resignation of Mike Farrar as Non-Executive Director following his appointment as Interim Permanent Secretary of the Northern Ireland Executive Department of Health. CEO Carolyn Cross expressed gratitude for Farrar’s contributions, noting his expertise was invaluable during a crucial growth period, and wished him success in his new role.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, to prevent and treat infections, including those from antibiotic-resistant bacteria. Their patented technology provides a safe, rapid, and effective alternative to traditional antibiotics, addressing significant healthcare challenges.
YTD Price Performance: 17.14%
Average Trading Volume: 262,848
Technical Sentiment Signal: Sell
Current Market Cap: £45.43M
For an in-depth examination of OBI stock, go to TipRanks’ Stock Analysis page.